Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Study of the Contribution of Mutant p53/YAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Multicenter, non-interventional, retrospective/prospective study of a biological nature, on patients affected by head and neck tumors, for which the collection and use of tissue samples is planned for the study of the mutational profile, the transcriptional profile and the proteomic profile.

Who May Be Eligible (Plain English)

Who May Qualify: - Age over 18 - Patients with squamous cell tumors of the oral cavity, pharynx or larynx - Surgical patients with primary HNSCC tumors, who have not had previous tumors in other sites or adjuvant treatments prior to surgery. - Availability of adequate material (tissue) for the planned analyses - Availability of follow-up data for at least one year (retrospective part) - Written willing to sign a consent form (prospective part and/or, for the retrospective part, traceable patients and/or patients in follow-up and/or if necessary for the legal nature/institutional purposes of the participating centers). Who Should NOT Join This Trial: - Presence of distant metastases at the time of diagnosis - Previous head and neck cancer - Second cancer undergoing treatment or follow-up for less than 5 years Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age over 18 * Patients with squamous cell tumors of the oral cavity, pharynx or larynx * Surgical patients with primary HNSCC tumors, who have not had previous tumors in other sites or adjuvant treatments prior to surgery. * Availability of adequate material (tissue) for the planned analyses * Availability of follow-up data for at least one year (retrospective part) * Written informed consent (prospective part and/or, for the retrospective part, traceable patients and/or patients in follow-up and/or if necessary for the legal nature/institutional purposes of the participating centers). Exclusion Criteria: * Presence of distant metastases at the time of diagnosis * Previous head and neck cancer * Second cancer undergoing treatment or follow-up for less than 5 years

Treatments Being Tested

BIOLOGICAL

Culture of organoids

Culture of organoids prepared from both the primary tumor and the respective relapse, using the material from the prospective part of the study, the response to treatment will be carried out by macroscopic analysis, evaluating the size and number of organoids before and after treatment,

Locations (1)

IRCCS National Cancer institute
Roma, Rome, Italy